• Surveys of individuals with AR conducted in Europe 3 indicate that poorly controlled AR has a substantial detrimental impact on quality of life (QoL), as well as the additional burden imposed by the development and exacerbation of comorbid conditions. 4 A health economic assessment, reflective of Spanish clinical practice, was conducted to determine the relative impact of treatment with Oralair®, Grazax®, Pangramin®, Pollinex Quattro®, and symptomatic drug treatment (SDT) on clinical effects and healthcare costs in patients with moderate-to-severe grass pollen-induced AR. • This analysis covers a 9-year time horizon. Based on the literature 10 and consultation of a Spanish clinical expert, it is assumed that after 3 years of immunotherapy treatment, a sustained effect for 6 additional years is maintained. As a consequence, data from the clinical trials are extrapolated to a 9-year time horizon, assuming a constant effect from years 4 to 9. The model has a cycle length of one year, and the grass pollen season has a length of 3 months.
• Baseline characteristics of the modelled cohort reflect the patient characteristics in the clinical trials in the meta-analysis. Patients included in the model suffer from AR to grass pollen and/or conjunctivitis with a positive grass allergen-specific skin prick test and/or raised serum grass allergen-specific IgE.
Patients were 32 years of age, on average.
• The analysis was conducted from the healthcare payer perspective. Hence, only direct costs incurred by a payer were considered. Discount rates were set at 3% per annum for both costs and effects over a time horizon beyond one year.
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Literature review & meta-analysis
• The following steps and accompanying data are presented in Table 1. • A literature review was conducted in the PubMed database to identify Hence, data from Alutard®, a subcutaneous allergen compound, has been used as a proxy to estimate the efficacy of Pangramin®.
• Subsequently, efficacy data, reported as symptom scores, were extracted for the treatment arms of the included studies, along with the corresponding standard deviations and number of patients treated.
• Different instruments to assess symptom severity were used among the included • The Rhinitis Symptom Utility Index (RSUI), a preference-based utility index based on rhinitis symptoms, has been used to estimate utility values for each symptom score.
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Transition probabilities
• Spanish-specific data for AIT discontinuation rates were not available. A paper on prescription renewal rates in the second and third year of treatment in Germany was used to estimate persistence.
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• A long-term observational study • General population mortality rates were obtained from the Spanish National
Institute of Statistics (INE). A prospective cohort study indicated a hazard ratio
of approximately 1.5 for asthmatics compared to general population mortality rates.
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Costs
• All AIT treatments were administered during 3 calendar years according to their prescribing and dosing information. Retail drug prices were obtained from botplus (available at: www.portalfarma.com), with the exception of the price for Oralair®, which was provided by Stallergenes.
• Resource use per comparator were obtained from the FERIN registry database.
Average unit costs for health care services and asthma were sourced from eSalud and published articles 17 .
Model assumptions
• Data from Alutard®, a subcutaneous allergen compound, has been used as a proxy to estimate the efficacy of Pangramin®.
• Patients who discontinue AIT generate costs and effects associated with the SDT arm.
• Effects of AIT in terms of symptom scores and utilities at 3 years are extrapolated into a time horizon of 9 years.
• Patients are treated for a maximum of three years.
• Once a patient develops asthma, there will be no remission.
• The grass pollen season has a length of 90 days.
• Table 2 presents the distribution of the total costs over the separate cost components for each comparator. Results indicate that the major cost drivers are AIT treatment costs and costs for specialist visits. Subcutaneously-administered compounds are associated with higher AIT assistance costs, as a healthcare professional is required to administer the injections.
• Treatment with Oralair® generates the highest number of total quality-adjusted life years (QALYs). This may be explained by the higher efficacy estimates relative to Grazax®, Pollinex Quattro® and SDT, and higher persistence rates relative to Pangramin®.
• Efficacy was estimated using an indirect comparison of available published clinical trials, as head-to-head comparative data is not currently available.
• Data from Alutard®, a subcutaneous allergen compound, has been used as a proxy to estimate the efficacy for Pangramin®
• Differences observed in symptom scores between drugs observed after 3 years were assumed to remain constant until 9 years.
• The impact of adverse events were not considered in the analysis.
The analysis suggests Oralair® to be a cost-effective treatment option relative to • Table 3 indicates that the higher incremental costs and effects of Oralair® versus Pangramin®, Pollinex Quattro® and SDT result in cost-effectiveness ratios of € 6,931, € 9,703, € 9,517 per QALY, respectively. Oralair® was predicted to be the dominant treatment strategy in comparison to Grazax® due to higher incremental QALYs and cost savings.
• Sensitivity analyses indicated that in 62% and 73% of the simulations, positive incremental effects are estimated for Oralair® compared to Grazax® and Pangramin®, respectively.
• In all comparisons, incremental costs are sensitive to inputs in the model on the length of the pollen season (Oralair ® is administered pre-and co-seasonally) and persistence of AIT. The incremental QALYs are mainly sensitive to changes in drug efficacy estimates, because these are directly linked to utility values from the RSUI.
• At a WTP threshold of €20,000 Oralair ® had a 65% probability being the most cost-effective treatment.
• Oralair® is an allergen extract tablet indicated as sublingual immunotherapy (SLIT) for the treatment of moderate-to-severe seasonal, grass pollen-induced AR.
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In Spain, alternative allergy immunotherapy (AIT) treatments include Grazax®, Pangramin®, and Pollinex Quattro®.
• Since head-to-head comparative data is not currently available, the relative effects and healthcare costs of these treatments have yet to be assessed in context of Spain.
This may facilitate healthcare decision-making, as providers need to make informed decisions on health benefits and cost consequences associated with interventions. 
General model characteristics and structure
A Markov model (Figure 1 ) was applied to predict the distribution of patients over a number of health states over a sequence of discrete time periods after receiving therapy.
This analysis covers a 9-year time horizon. Based on literature 10 and consultation of a Spanish clinical expert, it is assumed that after 3 years of immunotherapy treatment, a sustained effect for 6 additional years is maintained. As a consequence, data from the clinical trials are extrapolated to a 9-year time horizon, assuming a constant effect from years 4 to 9. The model has a cycle length of one year, and the grass pollen season has a length of 3 months.
Baseline characteristics of the modelled cohort reflect the patient characteristics in the clinical trials in the meta-analysis. Patients included in the model suffer from AR to grass pollen and/or conjunctivitis with a positive grass allergen-specific skin prick test and/or raised serum grass allergen-specific IgE. Patients were 32 years of age, on average.
The analysis was conducted from the healthcare payer perspective. Hence, only direct costs incurred by a payer were considered. Discount rates were set at 3% per annum for both costs and effects over a time horizon beyond one year. 
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